Kristi Rosa

IMvigor011 shows post-cystectomy ctDNA timing and levels predict relapse, while adjuvant atezolizumab clears ctDNA and extends survival in MIBC.

Phase 2 results showed efficacy and tolerability of disitamab vedotin in pretreated HER2+ and HER2-low urothelial cancer.

In certain patients with prostate cancer, darolutamide enhanced PSMA expression, according to the Daro-PET study.

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

The MagnetisMM-30 trial reveals promising early responses and manageable safety for elranatamab and iberdomide in relapsed multiple myeloma patients.

The SAVE regimen demonstrates promising efficacy in newly diagnosed AML, achieving high response rates but raises concerns about myelosuppression.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.

Tarlatamab-dlle combined with anti-PD-L1 therapy shows remarkable survival rates and manageable safety in extensive-stage small cell lung cancer patients.

SHR-4849 shows promising efficacy and manageable safety in relapsed small cell lung cancer, highlighting its potential as a targeted treatment option.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable HCC patients, as shown in the TALENTACE trial.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation due to adverse effects significantly.

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

Dose adjustments enabled longer NALIRIFOX exposure and survival in select metastatic PDAC patients, with favorable clinical profiles despite multiple metastatic sites.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after suboptimal first-line therapy.